Skip to main content

New and emerging treatments for advanced prostate cancer.

Publication ,  Journal Article
George, DJ; Kantoff, PW; Lin, DW
Published in: Clin Adv Hematol Oncol
June 2011

Historically, the treatment of metastatic castration-resistant prostate cancer (CRPC) has been limited to chemotherapeutic regimens that did not improve patient survival. In 2004, clinical studies began to demonstrate significant improvements in patient outcomes, including overall survival, with docetaxel versus mitoxantrone chemotherapy. Since these pivotal trials, the combination of docetaxel plus prednisone has become a standard of care for patients with metastatic CRPC. However, the limited survival benefit achieved with this regimen prompted several investigations into the development of alternative therapeutic options. Recent advances have now led to an unprecedented number of new drug approvals within the past year, providing many new treatment options for patients with metastatic CRPC. Sipuleucel-T, considered a new paradigm in cancer treatment, is the first such immunotherapeutic agent approved by the US Food and Drug Administration. Other successes include abiraterone acetate, the first androgen biosynthesis inhibitor, and cabazitaxel, a novel microtubule inhibitor, both of which have demonstrated improved survival following docetaxel failure. The bone-targeting agent denosumab, also recently approved in this setting, offers these patients significant improvement in the prevention of skeletal-related events. The data supporting the approval of each of these agents are described in this monograph, as are current approaches in the treatment of metastatic CRPC and ongoing clinical trials of novel treatments and strategies. The experts also discuss several of the issues regarding the introduction of these novel agents into clinical practice for metastatic CRPC patients.

Duke Scholars

Published In

Clin Adv Hematol Oncol

ISSN

1543-0790

Publication Date

June 2011

Volume

9

Issue

6 Suppl 12

Start / End Page

1 / 15

Location

United States

Related Subject Headings

  • Prostatic Neoplasms
  • Oncology & Carcinogenesis
  • Male
  • Immunotherapy
  • Humans
  • Antineoplastic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
George, D. J., Kantoff, P. W., & Lin, D. W. (2011). New and emerging treatments for advanced prostate cancer. Clin Adv Hematol Oncol, 9(6 Suppl 12), 1–15.
George, Daniel J., Philip W. Kantoff, and Daniel W. Lin. “New and emerging treatments for advanced prostate cancer.Clin Adv Hematol Oncol 9, no. 6 Suppl 12 (June 2011): 1–15.
George DJ, Kantoff PW, Lin DW. New and emerging treatments for advanced prostate cancer. Clin Adv Hematol Oncol. 2011 Jun;9(6 Suppl 12):1–15.
George, Daniel J., et al. “New and emerging treatments for advanced prostate cancer.Clin Adv Hematol Oncol, vol. 9, no. 6 Suppl 12, June 2011, pp. 1–15.
George DJ, Kantoff PW, Lin DW. New and emerging treatments for advanced prostate cancer. Clin Adv Hematol Oncol. 2011 Jun;9(6 Suppl 12):1–15.

Published In

Clin Adv Hematol Oncol

ISSN

1543-0790

Publication Date

June 2011

Volume

9

Issue

6 Suppl 12

Start / End Page

1 / 15

Location

United States

Related Subject Headings

  • Prostatic Neoplasms
  • Oncology & Carcinogenesis
  • Male
  • Immunotherapy
  • Humans
  • Antineoplastic Agents